A case of advanced gastric cancer successfully treated with trastuzumab, capecitabine, and Cisplatin therapy followed by curative resection

We report a case of human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer successfully treated with combination therapy of trastuzumab, capecitabine, and cisplatin, followed by a curative resection. A 23-year-old woman was diagnosed with advanced type 3 gastric cancer, and...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 41; no. 12; p. 2311
Main Authors Kato, Shigeru, Asao, Yoshito, Aisu, Yuki, Honda, Kotaro, Ando, Yasuhisa, Nishino, Hiroto, Nishiuchi, Aya, Kadokawa, Yoshio, Machimoto, Takafumi, Furuyama, Hiroaki, Yoshimura, Tsunehiro
Format Journal Article
LanguageJapanese
Published Japan 01.11.2014
Subjects
Antibodies, Monoclonal, Humanized - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Capecitabine
Cisplatin - administration & dosage
Combined Modality Therapy
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Female
Fluorouracil - administration & dosage
Fluorouracil - analogs & derivatives
Gastrectomy
Humans
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Stomach Neoplasms - surgery
Trastuzumab
Young Adult
Online AccessGet more information

Cover

More Information
Summary:We report a case of human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer successfully treated with combination therapy of trastuzumab, capecitabine, and cisplatin, followed by a curative resection. A 23-year-old woman was diagnosed with advanced type 3 gastric cancer, and the clinical findings were T3N0M0, StageIIA. A laparoscopic exploration revealed that it was a CY1 unresectable StageIV cancer. Initially, docetaxel, cisplatin, and S-1 therapy was chosen. However, the patient's HER2 status proved to be positive (IHC 3+), and so trastuzumab, capecitabine and cisplatin therapy was administered. After four cycles, the tumor significantly decreased in size, suggesting a partial response(PR). A further laparoscopic exam showed no apparent dissemination or metastatic cancer cells. We performed a curative resection consisting of a laparoscopic distal gastrectomy and D2 lymphadenectomy. The patient's postoperative course has been uneventful. She has been alive for 4 months and is receiving adjuvant chemotherapy comprising trastuzumab and S-1.
ISSN:0385-0684